Which trial do we need? Early oral antibiotic therapy for the treatment of gram-negative bloodstream infections
Author:
Publisher
Elsevier BV
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference15 articles.
1. Seven versus 14 Days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial;Yahav;Clin Infect Dis,2019
2. Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial;von Dach;JAMA,2020
3. Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial;Molina;Clin Microbiol Infect,2022
4. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome;Kang;Antimicrob Agents Chemother,2005
5. Administration of a beta-lactam prior to vancomycin as the first dose of antibiotic therapy improves survival in patients with bloodstream infections;Amoah;Clin Infect Dis,2022
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Early transition to oral therapy in gram-negative bloodstream infections: what is the next step?;Clinical Microbiology and Infection;2024-04
2. Which trials do we need?;Clinical Microbiology and Infection;2024-04
3. Real-World Effectiveness of Intravenous and Oral Antibiotic Stepdown Strategies for Gram-Negative Complicated Urinary Tract Infection With Bacteremia;Open Forum Infectious Diseases;2024-03-28
4. Oral Beta-Lactams, Fluoroquinolones, or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Uncomplicated Escherichia coli or Klebsiella species Bacteremia from a Urinary Source;Open Forum Infectious Diseases;2023-12-27
5. Safety of early oral ambulatory treatment of adult patients with bloodstream infections discharged from the emergency department;Antimicrobial Agents and Chemotherapy;2023-11-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3